← Human Trials & Peer-Reviewed Studies
Differences in plasma apelin and visfatin levels between patients with type 1 diabetes mellitus and healthy subjects and response after acute hyperglycemia and insulin administration
Plain-language guide to PMID 23422767 (2012): placebo-controlled randomized controlled trial study of Insulin Lispro and Apelin in 52 subjects.
Key Facts
- PMID
- 23422767
- Journal
- Hormones (Athens, Greece)
- Year
- 2012
- Study type
- Randomized Controlled Trial
- Authors
- Alexiadou K et al. (6 authors)
- DOI
- 10.14310/horm.2002.1376
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Insulin Lispro and Apelin, published as a randomized controlled trial.
The aim of the present study was to determine differences in plasma apelin and visfatin concentrations between healthy subjects and patients with type 1 diabetes mellitus and to study the effect of hyperglycemia and insulin administration on their levels in patients with type 1 diabetes mellitus.
Who Took Part
The abstract describes 52 subjects taking part.
PubMed indexes the participants as adults.
One hundred patients with T1DM and 52 healthy subjects were examined.
Nine patients with type 1 diabetes and 9 controls participated in a further study.
How the Study Was Run
In design terms this was a randomized and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Insulin Lispro and who got the comparison, which limits bias.
Some subjects received a placebo instead of Insulin Lispro, giving a reference point.
In the main study, blood samples were taken after a 12-hour fast.
In a further study, an oral glucose tolerance test was performed on two occasions.
In session B, no insulin or placebo was administered.
Apelin, visfatin, insulin and glucose levels were measured at baseline and 10, 20, 30, 60, 90, 120, 150 and 180 min after glucose consumption.
What Was Measured
The subject headings attached to it are Apelin, Blood Glucose, Cholesterol, HDL, Diabetes Mellitus, Type 1, Fasting, Glucose Tolerance Test and Hyperglycemia.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Insulin Lispro and Apelin in 52 subjects.
The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2012 (Hormones (Athens, Greece)), a journal based in Switzerland.
More context: the Insulin Lispro compound page and the Apelin compound page, all human trials.
Our Notes on the Compounds
Insulin Lispro: A rapid-acting mealtime insulin analog; brands include Humalog, Admelog and Lyumjev.
Apelin: A peptide hormone family that acts on the heart and blood vessels; studied as an infusion in heart and lung research.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.